Format

Send to

Choose Destination
Ann Clin Transl Neurol. 2019 Jan 8;6(2):392-396. doi: 10.1002/acn3.712. eCollection 2019 Feb.

Brain histopathological study and prognosis in MOG antibody-associated demyelinating pseudotumor.

Author information

1
Department of Neurology The Third Affiliated Hospital of Sun Yat-Sen University Guangzhou 510630 China.
2
Department of Neurology the Second Affiliated Hospital of Guangzhou Medical University Guangzhou 510260 China.
3
State Key Laboratory of Oncology in South China Department of Pathology Collaborative Innovation Center for Cancer Medicine Sun Yat-sen University Cancer Center Guangzhou 510060 China.
4
State Key Laboratory of Oncology in South China Department of Medical Imaging Collaborative Innovation Center for Cancer Medicine Sun Yat-sen University Cancer Center Guangzhou 510060 China.
5
Department of Neurology 999 brain hospital Guangzhou 510510 China.
6
Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong China.
7
Priority Area Asthma and Allergy Research Center Borstel Airway Research Center North (ARCN) German Center for Lung Research (DZL) Borstel 23845 Germany.
8
Centre for Neuromuscular and Neurological Disorders Perron Institute University of Western Australia Perth Australia.

Abstract

Our objective was to examine the brain biopsies by histopathology and investigate the prognosis of patients with myelin oligodendrocyte glycoprotein antibody-associated demyelinating pseudotumor. The clinical, MRI, and histological features of two patients with myelin oligodendrocyte glycoprotein antibody-associated demyelinating pseudotumor were reviewed. Both patients were treated with steroid plus rituximab and followed up. The brain biopsies of both cases revealed T cells, macrophages, and complement-mediated demyelination, which was in accord with multiple sclerosis-like pathology. Moreover, both cases showed favorable response to steroid plus rituximab therapy. Our cases add a new variant to the myelin oligodendrocyte glycoprotein-encephalomyelitis spectrum, which favorably responds to immunotherapy.

Conflict of interest statement

The authors declare that no competing interests exist.

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center